ClinicalTrials.gg
Not yet recruitingNCT07846865TIRZE-PAPUpdated Nov 2, 2026

Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea

A Phase 2/3 interventional study of Continuous Positive Airway Pressure and Tirzepatide in Sleep Apnoea, Obesity & Overweight and Sleep Apnea Syndrome, Obstructive, sponsored by Woolcock Institute of Medical Research. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionSleep Apnea, ObstructiveRegistry: Sleep Apnea SyndromesReclassifiedWhy we changed it
Registry
Sleep Apnea Syndromes — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sleep Apnea, Obstructive
Why
  1. The study's listed conditions name Sleep Apnea, Obstructive, a narrower term within Sleep Apnea Syndromes.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Woolcock Institute of Medical Research · Phase 2/3, Interventional, and Treatment

Updated Nov 2, 2026Study documents postedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Sleep Apnea, Obstructive with a site in Australia — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Australia.

Planned enrollment
13th of 57
256 · median 42
Started
2026
with 5 others
Phase 2/3
Only one
of the 62
Primary completion
2028-12
later than 17 of 18 live
Registered
62nd of 62
by date
Lead sponsor
3 of 62
Woolcock Institute of Medical Research

Among the 62 studies in Sleep Apnea, Obstructive with a site in Australia, this one is the 13th largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 17 of the 18 other live ones, and was the 62nd registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

16 of the 62 studies in Sleep Apnea, Obstructive with a site in Australia are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Sleep Apnea, Obstructive with a site in Australia, or all of them as a file.
02

Study summary

When used, continuous positive airway pressure (CPAP) is an effective treatment for obstructive sleep apnea (OSA), a condition that is mainly caused by overweight and obesity. However, CPAP is plagued by poor adherence and high rates of discontinued use leaving most patients undertreated and at risk of serious health complications. This study aims to test whether new effective weight loss pharmacotherapy is superior to CPAP for alleviating OSA and improving health outcomes.

Read the detailed description

The TIRZE-PAP study is a parallel randomised superiority trial comparing weight loss with weekly tirzepatide (15mg or the maximum tolerated dose) versus CPAP, in 256 people with moderate-severe OSA (AHI≥15/hr) and overweight or obesity (BMI: ≥27kg/m2). Participants allocated to CPAP will receive therapy as per usual care by their treating physician. Participants allocated to tirzepatide will undergo a 20-week stepped titration with a monthly increase of dose to a maximum 15mg (or maximum tolerated) by week 20. Outcomes will be collected over two 28-day periods commencing at baseline (pre-intervention weeks -4 to 0) and at follow-up (post-intervention weeks 48 to 52).

03

Conditions studied

  • Sleep Apnoea
  • Obesity & Overweight
  • Sleep Apnea Syndrome, Obstructive

Keywords

  • Continuous Positive Airway Pressure
  • Tirzepatide
  • Sleep Apnoea
  • Clinical Trial
  • weight loss
  • GLP1
  • Mounjaro
  • OSA
  • CPAP
  • comparative effectiveness
  • randomized
  • sleep apnea
  • GIP
04

In context

Sleep Apnea, Obstructive Reclassified

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 256 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Woolcock Institute of Medical Research is the lead sponsor of 17 studies on the registry; 12 are open to participants now.

Compared within Sleep Apnea, Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sleep Apnea Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females and Males aged ≥ 18 years at the time of signing
  • Moderate-severe OSA defined as an AHI ≥ 15/hr determined from a Type 1 or 2 sleep study conducted within the previous 12 months with a clinician recommendation for CPAP therapy.
  • Moderate overweight or obesity defined as ≥ 27 kg/m2. (Adjusted to BMI ≥ 25 kg/m2 for Asian populations as per WHO guidelines (WHO Expert Consultation (2004))
  • No to tirzepatide use as per Australian Product Information
  • Home internet access to enable cloud storage of SleepTracker-AI in-home BDI.
  • Fluent English literacy and able to provide informed consent.

Exclusion criteria

Exclusion Criteria:

OSA or other respiratory related criteria:

  • Respiratory failure including obesity hypoventilation syndrome (OHS) or daytime hypercapnia or moderate-severe (COPD) with /FVC ratio\<0.7 and FEV1\<80% predicted (GOLD criteria).
  • Driver occupation with excessive sleepiness (Epworth Sleepiness Scale >=16) or sleepiness-related motor vehicle accident or near accident within 12 months prior to enrolment
  • Current or prior (≤3 months) OSA treatment with mechanical therapy (CPAP, MAS, Positional)
  • >50% respiratory events with Cheyne-Stokes Respiration (CSR) or Central Sleep Apnoea (CSA)
  • Relative or absolute to CPAP including chronic cranial injury; recurrent pneumothorax; indication for oral-pharyngeal surgery, significant craniofacial abnormalities that may affect breathing, or are unwilling to use CPAP
  • Any previous or planned surgery for OSA or major ear, nose or throat surgery, including tonsillectomy and adenoidectomy that still may affect breathing (NB: Inclusion of a participant with more minor ear, nose or throat surgery (for example, deviated septum) will be at the investigator's discretion)

Glycaemia related criteria:

  • ≥ 48 mmol/mol (6.5%) at screening
  • Type 1 or type 2 diabetes mellitus
  • Treatment with glucose-lowering agent(s) within 90 days before screening
  • Treatment with a GLP-1 receptor agonist within 90 days before screening

Obesity related criteria:

  • A self-reported change in body weight >5 kg or >5% within 90 days before baseline
  • Treatment with medication for the indication of obesity within 90 days before baseline and/or currently enrolled in a weight loss program

Other criteria:

  • Pregnancy/breast feeding or planning a pregnancy during the trial period
  • Relative or absolute contraindication to tirzepatide including needle phobia
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
256 participants (estimated)

Study arms

  • Active comparator
    Continuous Positive Airway Pressure (CPAP)

    Device: Continuous Positive Airway Pressure

  • Experimental
    Tirzepatide

    Drug: Tirzepatide

Interventions

  • DeviceContinuous Positive Airway Pressure

    CPAP will be set at a fixed pressure that abolishes apnoeas and hypopneas determined from an in-lab titration study or set according to a pre-determined algorithm using an auto-titrating machine at home. Participants may also be counselled on losing weight with diet and exercise as per usual practice.

  • Patients allocated to weight loss with tirzepatide will be managed by the study dietitian. The tirzepatide formulation is administered subcutaneously once weekly using single-use injection pens. Participants will undergo a 20-week dose escalation phase (starting at 2.5mg/week for 4 weeks, 5 mg/week for 4 weeks, 7.5mg/week for 4 weeks, 10mg/week for 4 weeks, 12.5mg/week for 4 weeks) followed by a dose maintenance phase of 15mg/week for the remainder of the 12-month study period. Participants unable to tolerate the next highest dose will be maintained on the maximum tolerable dose for the duration of the intervention.

07

What researchers measure

Primary outcomes

  1. Breathing Disturbance Index (BDI)

    BDI is the primary severity metric of OSA in the trial which is measured by the number of breathing disturbances per hour of sleep. This is measured using contactless mattress-based OSA monitors (SleepTracker-AI) that can automatically and reliably measure true OSA alleviation every night for the entire period of sleep.

    Time frame: The mean BDI measured over 28 nights of monitoring is calculated for baseline (Weeks -4 to 0) and follow-up (Weeks 48 to 52)

Secondary outcomes

  1. Hypoxia - Oxygen Desaturation Index (ODI 3%)

    ODI 3% is calculated as the number of oxygen desaturation events ≥3% per hour as a percentage of time in bed, estimated using at-home oximetry (RingConn Gen 2).

    Time frame: ODI 3% will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12month follow-up.

  2. Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a Score

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a Score is used to assess participant-reported levels of alertness, sleepiness, and tiredness and the functional impairments associated with sleep problems or reduced alertness over the past 7 days. Impairment ranges from a minimum of 5 (no impairment) to a maximum of 40 (maximal impairment).

    Time frame: Collected at Baseline and 3,6,9 and 12 months.

  3. Epworth Sleepiness Scale (ESS)

    The Epworth Sleepiness Scale (ESS) measures self-reported subjective sleepiness using an 8-item questionnaire. Sleepiness ranges from a minimum of 0 (no sleepiness) to a maximum of 24 (severe sleepiness).

    Time frame: Collected at Baseline and 3,6,9 and 12 months.

  4. Ambulatory Blood Pressure - Sleep Systolic Blood Pressure (SBP)

    Sleep SBP is measured hourly, using an ambulatory blood pressure monitor, for a self-reported sleep period.

    Time frame: Baseline and Week 52

  5. Cardiometabolic Fasted Blood Markers - Low-Density Lipoproteins (LDL)

    Low-density lipoproteins are measured from fasted venous blood.

    Time frame: Screening and Week 52

  6. Cardiometabolic Fasted Blood Markers - HbA1c

    HbA1c, or glycated haemoglobin, assesses long-term glycaemic control. It is measured from fasted venous blood.

    Time frame: Screening and Week 52

Other outcomes

  1. Hypoxic Burden

    This is an oximetry-derived measurement using established algorithms. Hypoxic burden measures are quantified from nightly at-home oximetry acquired using an oximeter device (RingConn Gen 2).

    Time frame: The mean nightly hypoxic burden measured over 7-10 nights of monitoring is calculated for baseline and 12 month follow-up.

  2. Short Form Functional Outcomes of Sleep Questionnaire (FOSQ-10)

    The Short Form Functional Outcomes of Sleep Questionnaire (FOSQ-10) is used to assess the impact of sleep disorders/excessive sleepiness on daily functioning. Function ranges from a minimum of 4 (low function) to a maximum of 20 (good function).

    Time frame: Baseline and 3, 6, 9 and 12 months.

  3. Cardiometabolic Fasted Blood Markers - Glucose

    Glucose is measured from fasted venous blood.

    Time frame: Screening and Week 52

  4. Cardiometabolic Fasted Blood Markers - Triglycerides [TAG]

    Triglycerides are measured from fasted venous blood.

    Time frame: Screening and Week 52

  5. Cardiometabolic Fasted Blood Markers - High-Density Lipoproteins (HDL)

    High-density lipoproteins are measured from fasted venous blood.

    Time frame: Screening and Week 52

  6. Cardiometabolic Fasted Blood Markers - Total Cholesterol

    Total cholesterol is measured from fasted venous blood.

    Time frame: Screening and Week 52

  7. Ambulatory Blood Pressure - Sleep Diastolic Blood Pressure (DBP)

    Sleep DBP is measured hourly over 24 hours using an ambulatory blood pressure monitor, segmented for a self-reported sleep period.

    Time frame: Baseline and Week 52

  8. Ambulatory Blood Pressure - Wake Systolic Blood Pressure (SBP)

    Wake SBP is measured hourly over 24 hours using an ambulatory blood pressure monitor, segmented for a self-reported wake period.

    Time frame: Baseline and Week 52

  9. Ambulatory Blood Pressure - Wake Diastolic Blood Pressure (DBP)

    Wake DBP is measured hourly over 24 hours using an ambulatory blood pressure monitor, segmented for a self-reported wake period.

    Time frame: Baseline and Week 52

  10. Ambulatory Blood Pressure - 24-hour Mean Arterial Pressure (MAP)

    24-hour MAP is calculated hourly over 24 hours using an ambulatory blood pressure monitor. MAP = DBP + (SBP - DBP)/3

    Time frame: Baseline and Week 52

  11. Office Blood Pressure - Systolic Blood Pressure (SBP)

    SBP is measured using an automated blood pressure machine after sitting quietly for 5 minutes.

    Time frame: Baseline and Week 52

  12. Office Blood Pressure - Diastolic Blood Pressure (DBP)

    DBP is measured using an automated blood pressure machine after sitting quietly for 5 minutes.

    Time frame: Baseline and Week 52

  13. Anthropometry - Body Mass Index (kg/m^2)

    BMI is calculated as weight in kilograms, divided by height measured in metres squared.

    Time frame: Baseline and Week 52

  14. Anthropometry - Weight (kg)

    Weight is measured in kilograms.

    Time frame: Baseline and Week 52

  15. Anthropometry - Body Weight (% change)

    Change in Weight is calculated as a percentage of change from baseline to 52-weeks.

    Time frame: Baseline and Week 52

  16. Anthropometry - Waist Circumference

    Waist circumference is measured in centimetres, using a tape measure positioned in line with the superior iliac crest of the hip.

    Time frame: Baseline and Week 52

  17. Anthropometry - Neck Circumference

    Neck circumference is measured in centimetres, using a tape measure positioned inferior to the laryngeal prominence.

    Time frame: Baseline and Week 52

  18. CAmbridge Neuropsychological Test Automated Battery (CANTAB) Multitasking Test

    The Multitasking Test is used to assess executive functioning and cued attentional set shifting.

    Time frame: Baseline and Week 52

  19. CANTAB Spatial Working Memory Task

    The Spatial Working Memory Task is used to assess working memory and strategy and is applicable in the assessment of general cognitive function.

    Time frame: Baseline and Week 52

  20. Psychomotor Vigilance Task (PVT)

    The PVT is used to assess a participant's level of alertness.

    Time frame: Baseline and Week 52

  21. Blood-Based Neurodegeneration Biomarkers - Amyloid Beta

    Amyloid Beta, a peptide associated with Alzheimer's disease, is measured from fasted venous blood.

    Time frame: Baseline and Week 52

  22. Blood-Based Neurodegeneration Biomarkers - Phosphorylated Tau

    Phosphorylated Tau \[p-Tau-217\], a tau protein with added phosphate groups, is measured from fasted venous blood.

    Time frame: Baseline and Week 52

  23. Blood-Based Neurodegeneration Biomarkers - Glial Fibrillary Acidic Protein (GFAP)

    GFAP, a structural protein found in astrocytic cells, is measured from fasted venous blood.

    Time frame: Baseline and Week 52

  24. Hypoxia - Time Spent With SpO2<88%

    Time spent with SpO2\<88% is calculated as the time spent with oxygen saturation below 88% as a percentage of time in bed, estimated using at-home oximetry.

    Time frame: Hypoxia outcomes will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12months.

  25. Hypoxia - Minimum SpO2

    Minimum SpO2 is calculated as the minimum oxygen saturation reached during time in bed, estimated using at-home oximetry.

    Time frame: Hypoxia outcomes will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12 month follow-up

  26. Hypoxia - Average Desaturation

    Average desaturation is calculated as the mean of all desaturation events \>=3% during time in bed, estimated using at-home oximetry.

    Time frame: Hypoxia outcomes will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12 month follow-up

  27. Breathing Disturbance Index (BDI)

    BDI is measured by the number of breathing disturbances per hour of sleep using contactless mattress-based OSA monitors (SleepTracker-AI).

    Time frame: Nightly for 12-month treatment duration.

  28. Anthropometry - Weight (Self-Measured)

    Weight (kg) - self-measured at home

    Time frame: At Baseline, 3, 6, and 9 months

08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Non-identifiable IPD will become available one year after publication and will be available for ten years.

Access criteria: A copy of the non-identifiable dataset may be requested by academic collaborators not affiliated with the Woolcock Institute of Medical Research through a data request form which outlines the investigators, aims and hypotheses, data to be included, a statistical analysis plan, ethics approval, and security measures. Data can be shared with the participant or their personal health care providers regarding any potential incidental findings upon request.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Nov 2, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionEpworth Sleepiness Scale (ESS): how it is measured was reworded
  • DescriptionPatient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a Score: how it is measured was reworded
  • Descriptionother outcomeShort Form Functional Outcomes of Sleep Questionnaire (FOSQ-10): how it is measured was reworded
Nov 2, 2026
Title
Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial
Nov 2, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Nov 2, 2026
    Documents Study protocol ↗ posted
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionEpworth Sleepiness Scale (ESS): how it is measured was reworded
    • DescriptionPatient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a Score: how it is measured was reworded
    • Descriptionother outcomeShort Form Functional Outcomes of Sleep Questionnaire (FOSQ-10): how it is measured was reworded
    Title Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial
    + 2 other changes: verification date and arm descriptions
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07846865
Lead sponsor
Woolcock Institute of Medical Research
Responsible party
Craig Phillips (Associate Professor, Woolcock Institute of Medical Research) — Principal investigator
First posted
Sep 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Craig Phillips, PhD
Contact
c.phillips@mq.edu.au
02 9805 3000
Julia Chapman, PhD
Contact
julia.chapman@woolcock.org.au
Craig Phillips
principal investigator · Woolcock Institute of Medical Research and Macquarie Medical School, Macquarie University, Sydney, NSW, Australia
Ron Grunstein
principal investigator · Woolcock Institute of Medical Research and Macquarie Medical School, Macquarie University, Sydney, NSW, Australia
Camilla Hoyos, PhD
study chair · Woolcock Institute of Medical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion